Physician profile
David Liska
NPI 1902063589
$9,468.79
in general payments reported to CMS, 2019-2025
18 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 81% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2021: $3,919 · 2022: $1,847 · 2023: $572 · 2024: $885 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,403 · Travel and Lodging: $565 · Consulting Fee: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.89 |
| Travel and Lodging | $565.34 |
| Consulting Fee | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation | $3,834.24 | 2021 | |
| Davol INC. | $1,500.00 | 2022 | |
| Medtronic, INC. | $910.88 | 2022-2025 | Eea, Signia, Ligasure |
| Intuitive Surgical, INC. | $743.67 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $544.77 | 2021-2025 | Myrisk |
| Ethicon US, LLC | $420.72 | 2022-2025 | Enseal, Echelon Flex, Harmonic |
| Aroa Biosurgery Incorporated | $274.75 | 2022-2025 | |
| Allergan, INC. | $261.22 | 2019-2022 | |
| Dilon Technologies, INC. | $233.48 | 2025 | Hemoblast Bellows |
| Abbvie INC. | $186.51 | 2023-2025 | |
| Covidien LP | $157.81 | 2019 | |
| Genzyme Corporation | $128.54 | 2024 | |
| Boston Scientific Corporation | $118.34 | 2025 | Axonics |
| Ferring Pharmaceuticals INC. | $105.98 | 2023 | Rebyota |
| Guard Medical INC. | $25.88 | 2025 | Npseal |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $22.00 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Liska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.